SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time toxicity challenges ...

Treatment responses were rapid, with median time to first response of 0.95 months, supporting clinical utility in aggressive, high-risk R/R MCL post–BTK inhibitor failure. Efficacy outcomes paralleled ...

Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted therapy alone in 23%, reflecting heterogeneous, risk- and access-driven ...

Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study Durable benefits persisted at three years and showed a favorable long-term ...

Our immune systems have the thankless jobs of guarding us from bacterial and viral invaders and preventing cancer development. Most of the time, we do not notice this hard work because the invaders ...